David Kalergis

David Kalergis (born December 9, 1948) is an American life sciences entrepreneur and author. He co-founded and chaired Atelerix Life Sciences Inc., a Charlottesville, Virginia, U.S.-based biotechnology and pharmaceutical company developing novel treatments for the reversal of opioid induced respiratory depression. He co-founded the company in 2020 with Stephen Lewis, PhD, James Bates, MD/PhD, and Ben Gaston, MD. He retired from this position in 2023.

Previously, he co-founded Diffusion Pharmaceuticals in 2001 with American chemical engineer John L. Gainer. Kalergis became Diffusion's CEO in 2004, retaining that position until 2020, when he left to create Atelerix Life Sciences. During this time, he drew extensively on his career in law, business, and clinical trials implementation to advance the company to Phase 3 clinical trials status and into a NASDAQ publicly traded entity. Under Kalergis' leadership, Diffusion Pharmaceuticals has been cited for advancing improved cancer treatments, conducting multicenter clinical trials of a novel therapeutic for brain cancers, including glioblastoma multiforme. Diffusion Pharmaceuticals has also conducted clinical trials for the treatment of oxygen deficiencies associated with COVID-19 and acute stroke.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.